LXEOLexeo Therapeutics Inc. Common Stock
4.880USD-9.12%Mkt Cap: 400.39M $P/E: —3d ago
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene the…
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
| Headline | Source | Time |
|---|---|---|
Older | ||
 What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the 10 best stocks under $10 that could triple. On June 15, Lexeo Therapeutics Inc. (NASDAQ:LXEO) disclosed that it has finalized the critical trial protocol of SUNRISE-FA 2. The company also finalized the statistical analysis plan meant to offer clinical evidence for submission of a Biologics License Application […] | IInsider Monkey | |
IInsider Monkey | ||